Wyeth withdraws pain product application from EMA review
This article was originally published in The Tan Sheet
Executive Summary
Wyeth Consumer Healthcare withdraws its centralized marketing authorization application for ibuprofen/diphenhydramine hydrochloride 200 mg/ 25 mg soft capsules, the European Medicines Agency announces Jan. 15. The agency says Wyeth withdrew the application because the Committee for Medicinal Products for Human Use concluded the data submitted does not support a positive benefit-risk balance for the analgesic and sedating antihistamine combination to be used by adults whose pain keeps them awake. Wyeth applied for marketing authority for the product Dec. 4, 2008, and withdrew it while under review by CHMP
You may also be interested in...
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.